Search results for "urokinase"

showing 10 items of 36 documents

Cardio‐Renal Biomarker Soluble Urokinase‐Type Plasminogen Activator Receptor Is Associated With Cardiovascular Death and Myocardial Infarction in Pat…

2020

Background Risk stratification among patients with coronary artery disease ( CAD ) is of considerable interest due to the potential to guide secondary preventive therapies. Thus, we evaluated the predictive value of soluble urokinase‐type plasminogen activator receptor (su PAR ) levels for cardiovascular mortality and nonfatal myocardial infarction in patients with CAD . Methods and Results Plasma levels of su PAR were measured in a cohort of 1703 patients with documented CAD as evidenced by coronary angiography—including 626 patients with acute coronary syndrome and 1077 patients with stable angina pectoris. Cardiovascular death and/or nonfatal myocardial infarction were defined as main o…

Malemedicine.medical_specialtyTime FactorsEpidemiologyMyocardial InfarctionRenal functionCoronary Artery Disease030204 cardiovascular system & hematologyKidneyRisk AssessmentReceptors Urokinase Plasminogen Activatorsoluble urokinase‐type plasminogen activator receptorTroponin CCoronary artery disease03 medical and health sciences0302 clinical medicinePredictive Value of TestsRisk FactorsGermanyInternal medicineSecondary PreventionmedicineHumanscardiovascular diseasesMyocardial infarctionReceptorAgedOriginal Research030304 developmental biologyUrokinase0303 health sciencesbusiness.industryMiddle AgedPrognosismedicine.diseaseTroponinC-Reactive ProteinHeart Disease Risk FactorsCardiologybiomarkerBiomarker (medicine)FemaleKidney DiseasesCardiology and Cardiovascular MedicinebusinessPlasminogen activatorBiomarkersGlomerular Filtration Ratemedicine.drugJournal of the American Heart Association
researchProduct

Thrombolysis with saruplase versus streptokinase in acute myocardial infarction: five-year results of the PRIMI trial.

1999

Abstract Background Short-term safety and efficacy of thrombolysis with saruplase in acute myocardial infarction have been shown in several trials. To assess long-term outcome of patients treated with saruplase or streptokinase for myocardial infarction, a 5-year follow-up of patients included in the Pro-Urokinase in Myocardial Infarction Trial was performed. Methods and Results Follow-up data are available from 8 centers on 255 (92.4%) of 276 included patients. The 5-year mortality rate was comparable with 20.8% of patients in the saruplase group and 16.9% in the streptokinase group (odds ratio 1.29, 95% confidence interval 0.69 to 2.42). In both groups, a considerable number of fatal card…

Malemedicine.medical_specialtyStreptokinasemedicine.medical_treatmentMyocardial InfarctionAnginaCohort StudiesFibrinolytic AgentsRecurrenceAngioplastyInternal medicineMedicineHumansStreptokinaseThrombolytic TherapyMyocardial infarctionAngioplasty Balloon CoronaryCoronary Artery BypassAgedbusiness.industryOdds ratioThrombolysisMiddle Agedmedicine.diseaseSurvival AnalysisUrokinase-Type Plasminogen ActivatorConfidence intervalRecombinant ProteinsCerebrovascular DisordersCardiologySaruplaseFemaleCardiology and Cardiovascular Medicinebusinessmedicine.drugFollow-Up StudiesAmerican heart journal
researchProduct

Proteolytic Enzymes Clustered in Specialized Plasma-Membrane Domains Drive Endothelial Cells’ Migration

2016

In vitro cultured endothelial cells forming a continuous monolayer establish stable cell-cell contacts and acquire a "resting" phenotype; on the other hand, when growing in sparse conditions these cells acquire a migratory phenotype and invade the empty area of the culture. Culturing cells in different conditions, we compared expression and clustering of proteolytic enzymes in cells having migratory versus stationary behavior. In order to observe resting and migrating cells in the same microscopic field, a continuous cell monolayer was wounded. Increased expression of proteolytic enzymes was evident in cell membranes of migrating cells especially at sprouting sites and in shed membrane vesi…

0301 basic medicinekalininsepraseCell Membranesbeta1 integrinCelllcsh:MedicineurokinaseBiochemistryEpitheliumCell membrane0302 clinical medicineAnimal CellsMedicine and Health Sciencesdipeptidyl peptidase IVlcsh:ScienceMultidisciplinarybiologyVesicleProteolytic enzymesCell migrationProteasesEnzymesCell biologyLaboratory EquipmentCell Motilitymedicine.anatomical_structureBiochemistry030220 oncology & carcinogenesisEngineering and TechnologyBiological Culturesmatrix metalloproteinase 14Cellular Structures and OrganellesCellular TypesAnatomyResearch ArticleEquipmentCell MigrationResearch and Analysis MethodsGelatin MediaCell Linegelatinase B03 medical and health sciencescollagen type 4fibronectinmedicineHumansVesiclescollagen type 1gelatinase Alcsh:RCell MembraneBiology and Life SciencesEndothelial CellsProteinsMembrane ProteinsEpithelial CellsCell BiologyCulture MediaFibronectinBiological Tissue030104 developmental biologyMembrane proteinCell cultureProteolysisMicroscopy Electron ScanningEnzymologybiology.proteinlcsh:QCollagensDevelopmental BiologyPLOS ONE
researchProduct

Kondrat'eva ligation: Diels-Alder-based irreversible reaction for bioconjugation.

2014

International audience; Diversification of existing chemoselective ligations is required to efficiently access complex and well-defined biomolecular assemblies with unique and valuable properties. The development and bioconjugation applications of a novel Diels-Alder-based irreversible site-specific ligation are reported. The strategy is based on a Kondrat'eva cycloaddition between bioinert and readily functionalizable 5-alkoxyoxazoles and maleimides that readily react together under mild and easily tunable reaction conditions to afford a fully stable pyridine scaffold. The potential of this novel bioconjugation is demonstrated through the preparation of fluorescent conjugates of biomolecul…

[CHIM.THER]Chemical Sciences/Medicinal ChemistryLigandsCatalysis[CHIM.ANAL]Chemical Sciences/Analytical chemistryFluorescence Resonance Energy TransferOrganic chemistryNuclear Magnetic Resonance BiomolecularOxazoleschemistry.chemical_classificationBioconjugationCycloaddition ReactionMolecular Structure[CHIM.ORGA]Chemical Sciences/Organic chemistryChemistryBiomoleculeOrganic Chemistry[CHIM.CATA]Chemical Sciences/CatalysisFluorescenceUrokinase-Type Plasminogen ActivatorCycloaddition[CHIM.THEO]Chemical Sciences/Theoretical and/or physical chemistryEnzyme ActivationFörster resonance energy transferLigationPlasminogen activator[CHIM.CHEM]Chemical Sciences/CheminformaticsConjugateThe Journal of organic chemistry
researchProduct

MicroRNA expression profile in endometriosis: its relation to angiogenesis and fibrinolytic factors

2014

Study question Could an aberrant microRNA (miRNA) expression profile be responsible for the changes in the angiogenic and fibrinolytic states observed in endometriotic lesions? Summary answer This study revealed characteristic miRNA expression profiles associated with endometriosis in endometrial tissue and endometriotic lesions from the same patient and their correlation with the most important angiogenic and fibrinolytic factors. WHAT IS ALREADY KNOWN?: An important role for dysregulated miRNA expression in the pathogenesis of endometriosis is well documented. However, to the best of our knowledge, there are no reports of the relationship between angiogenic and fibrinolytic factors and mi…

AdultVascular Endothelial Growth Factor Amedicine.medical_specialtyAngiogenesisEndometriosisEndometriosisEndometriumThrombospondin 1EndometriumYoung Adultchemistry.chemical_compoundInternal medicinePlasminogen Activator Inhibitor 1microRNAmedicineHumansNeovascularization Pathologicbusiness.industryRehabilitationObstetrics and GynecologyMicroRNA Expression ProfileMiddle Agedmedicine.diseaseUrokinase-Type Plasminogen ActivatorVascular endothelial growth factorMicroRNAsVascular endothelial growth factor AEndocrinologymedicine.anatomical_structureReproductive MedicinechemistryCase-Control StudiesCancer researchFemalebusinessFibrinolytic agentHuman Reproduction
researchProduct

Thrombolytic therapy for submassive pulmonary embolism.

2012

Approximately 10% of all patients with acute pulmonary embolism (PE) die within the first three months after diagnosis. However, PE is not universally life-threatening, but covers a wide spectrum of clinical severity and death risk. Thrombolytic treatment is indicated patients with acute massive PE who are at high risk for early death, i.e. those patients who present with arterial hypotension and shock. On the other hand, low molecular-weight heparin or fondaparinux is adequate treatment for most normotensive patients with PE. Recombinant tissue plasminogen activator, given as 100 mg infusion over 2 h, is the treatment of choice for patients with PE, although older regimens using urokinase …

medicine.medical_specialtymedicine.medical_treatmentStreptokinaseVentricular Dysfunction RightClinical Biochemistry030204 cardiovascular system & hematologyFondaparinuxlaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled trialFibrinolytic AgentslawPolysaccharidesRisk FactorsInternal medicinemedicineHumansStreptokinaseThrombolytic Therapy030212 general & internal medicineIntensive care medicineUrokinaseClinical Trials as Topicbusiness.industryHeparinThrombolysisHeparin Low-Molecular-Weightmedicine.diseaseUrokinase-Type Plasminogen ActivatorTroponin3. Good healthPulmonary embolismRadiographyOncologyFondaparinuxTissue Plasminogen ActivatorAcute DiseaseCardiologybusinessPulmonary EmbolismBiomarkersmedicine.drugCohort studyBest practiceresearch. Clinical haematology
researchProduct

Chronisches thromboembolisches Cor pulmonale bei schrittmacherassoziierten rechtsatrialen Thromben: Pulmonale Thrombendarteriektomie mit Elektrodenen…

2008

Life-threatening chronic cor pulmonale occurred in a 22-year-old woman with congenital 3 degrees atrioventricular block, 6 years after implantation of a pacemaker and 3 1/2 years after removal of the pacemaker (the electrodes were too firmly attached to be removed). The emboli originated from the right-atrial thrombi which had formed around the electrodes left in situ. The embolic source shrank during systemic administration of urokinase, initially 600,000 IU in 60 min, then 100,000 IU per hour, and pulmonary perfusion improved transiently. Nonetheless the patient became breathless on the slightest physical exertion. Recurrent syncopal attacks with marked increase of pulmonary artery pressu…

Urokinasemedicine.medical_specialtyPulmonary thromboendarterectomybusiness.industrymedicine.medical_treatmentGeneral Medicinemedicine.diseaseRight atrialInternal medicinemedicine.arteryPulmonary arterymedicineCardiologyExertionbusinessAtrioventricular blockPerfusionmedicine.drugEndarterectomyDMW - Deutsche Medizinische Wochenschrift
researchProduct

Enhanced platelet thromboxane synthesis and reduced macrophage-dependent fibrinolytic activity related to oxidative stress in oral contraceptive-trea…

1996

Abstract In previous studies conducted in rats and in women, we have shown that oral contraceptive (OC) administration induced a platelet hyperaggregation simultaneously with an increased platelet lipid biosynthesis which might be related to lipid peroxidation. In the present study, we specifically studied the arachidonic acid and the fibrinolytic pathways in relation to the fatty acid composition in female rats treated for 6 weeks with OC (ethinyl estradiol plus lynestrenol). We found that platelets of treated animals were not only hyper-responsive to thrombin and ADP, but also to sodium arachidonate. In addition, the results of the thrombin-induced release of labeled arachidonic acid pre-…

Blood Plateletsmedicine.medical_specialtyErythrocytesPlatelet AggregationThromboxaneRadioimmunoassayLipid peroxidationRats Sprague-Dawleychemistry.chemical_compoundThromboxane A2Internal medicineLipid biosynthesisThromboembolismmedicineAnimalsArachidonic AcidFibrinolysisThromboxanesUrokinase-Type Plasminogen ActivatorRecombinant ProteinsRatsThromboxane B2Disease Models AnimalOxidative StressEndocrinology12-Hydroxyheptadecatrienoic acidchemistryMacrophages Peritoneal12-Hydroxyeicosatetraenoic acidArachidonic acidFemaleLipid PeroxidationCardiology and Cardiovascular MedicineContraceptives OralAtherosclerosis
researchProduct

Prognostic value of soluble urokinase plasminogen activator receptor in patients presenting to the emergency department with chest pain suggestive of…

2021

International audience; INTRODUCTION: Soluble urokinase plasminogen activator receptor (suPAR) is a prognostic biomarker of cardiovascular disease. OBJECTIVES: We aimed to evaluate the early prognostic value of suPAR in patients presenting to the emergency department (ED) with chest pain suggestive of acute coronary syndrome (ACS). PATIENTS AND METHODS: In a post-hoc analysis from a multicenter study including patients with a chest pain < 6 h, suPAR concentrations at ED admission were studied according to the outcome at 30-days. RESULTS: 198 patients (median age 56 years) in whom 16% had an ACS, were included. Fifteen (7.3%) patients presented a 30-day event. At ED admission, median (IQR…

AdultMale030213 general clinical medicineAcute coronary syndromemedicine.medical_specialty[SDV]Life Sciences [q-bio]Clinical BiochemistrySoluble urokinase plasminogen activator receptorDisease030204 cardiovascular system & hematologyChest painPrognosticGastroenterologyReceptors Urokinase Plasminogen ActivatorsuPARChest pain03 medical and health sciences0302 clinical medicinePredictive Value of TestsInternal medicinemedicineHumansIn patientAcute Coronary SyndromeReceptorAgedOutcomeAged 80 and overbusiness.industryEmergency departmentGeneral MedicineEmergency departmentMiddle Agedmedicine.diseasePrognosisED30-day event3. Good health[SDV] Life Sciences [q-bio]SuPARBiomarker (medicine)Femalemedicine.symptombusinessEmergency Service HospitalBiomarkers
researchProduct

Differential expression levels of urokinase-type plasminogen activator and cathepsin D in locally advanced laryngeal squamous cell carcinoma: Clinica…

2002

The expression levels and the prognostic impact of urokinase-type plasminogen activator (uPA) and cathepsin D (CD) were evaluated in patients with locally advanced laryngeal squamous cell carcinoma (LSCC). uPA and CD protein levels were determined by immunoluminometric or immunoenzymatic assays in the cytosol of paired sets of tumor tissues and corresponding adjacent normal mucosa (NLM) from 57 patients with stage III/IV LSCC and were correlated with a number of clinicobiological parameters of this tumor including anatomical site, tumor grade, nodal status, clinical stage, DNA ploidy, proliferation rate, and patient outcome. Median uPA levels were significantly higher in LSCC than in NLM (…

LarynxMaleCancer ResearchPathologymedicine.medical_specialtyClinical BiochemistryCathepsin D030204 cardiovascular system & hematologyBiologyPremisesLysosomal proteinaseCathepsin DPathology and Forensic Medicine03 medical and health sciences0302 clinical medicinemedicineBiomarkers TumorHumansLaryngeal carcinomaStage (cooking)030223 otorhinolaryngologyLaryngeal NeoplasmsAgedchemistry.chemical_classificationUrokinaseMiddle AgedUrokinase-Type Plasminogen Activatormedicine.anatomical_structureEnzymeOncologyEpidermoid carcinomachemistryTumor markers Urokinase-type plasminogena ctivatorMultivariate AnalysisCarcinoma Squamous CellFemalePlasminogen activatorSerine proteinasemedicine.drug
researchProduct